Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for patients with asthma and metabolic syndrome
IRCT20220305054199N1Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma and cardiometabolic risk (CMR) comparing Metformin plus standard treatment with Placebo plus standard treatment (2 arms). Primary endpoints: Blood sugar, Inflammatory markers and 2 more. Started Apr 2022; status: completed.
02
Drugs
metformin
03
Conditions
asthmacardiometabolic risk (CMR)
Beyond the preview
Go deeper on IRCT20220305054199N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220305054199N1.